Furan and benzofuran derivatives as privileged scaffolds as anticancer agents: SAR and docking studies (2010 to till date)
Preeti Patel(Indo Soviet Friendship College of Pharmacy), Harish Rajak(Guru Ghasidas Vishwavidyalaya), Ruchi Shakya(Indo Soviet Friendship College of Pharmacy), Sant Kumar Verma(Indo Soviet Friendship College of Pharmacy), Balak Das Kurmi(Indo Soviet Friendship College of Pharmacy), vishakha vishakha(Indo Soviet Friendship College of Pharmacy), Vivek Asati(Indo Soviet Friendship College of Pharmacy), Ghanshyam Das Gupta(Indo Soviet Friendship College of Pharmacy)
Cited by 57
Related Papers
Solid lipid nanoparticles: a review on recent perspectives and patents
|Expert Opinion on Therapeutic Patents|2020|323
Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs
|Life|2023|206
Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention
|Pharmacological Reports|2021|145
A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer
|Drug Delivery and Translational Research|2024|138
Micro- and nanocarrier-mediated lung targeting
|Expert Opinion on Drug Delivery|2010|121